Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 13c, provides guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.43 +1.69%
EPS Growth %: -60.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -60.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.82), $0.13 worse than the analyst estimate of ($0.69). Revenue for the quarter came in at $51.72 million versus the consensus estimate of $55.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $258.2 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
